CT放射组学预测晚期NSCLC一线EGFR-TKI进展后EGFR-T790M耐药突变
本研究纳入211例组织检测和135例ctDNA检测的晚期NSCLC患者,提取胸部平扫和/或增强CT的放射组学特征建模,预测一线EGFR-TKI失败后的EGFR-T790M突变。平扫、增强及联合模型AUC分别为0.844、0.811和0.897,外部验证中联合模型AUC为0.760,显示CT放射组学具有预测可行性。
要点
- 外周位置和胸膜凹陷征与EGFR-T790M突变相关。
- 平扫+增强CT联合放射组学模型预测效能最佳。
- 外部验证中联合模型对ctDNA检测的T790M预测AUC为0.760。
核心结论
- CT放射组学特征可用于预测晚期NSCLC一线EGFR-TKI进展后的EGFR-T790M耐药突变。
研究设计与样本
- 回顾性纳入211例组织检测(Cohort-1)和135例ctDNA检测(Cohort-2)的晚期NSCLC患者。
- Cohort-1用于建模,Cohort-2用于模型验证。
- 从胸部平扫和/或增强CT的肿瘤病灶提取放射组学特征,使用8种特征选择器和8种分类器算法建模。
关键影像表现/征象
- CT形态学表现中,外周位置和胸膜凹陷征与EGFR-T790M突变相关。
诊断标准与关键数值
- 平扫CT模型采用LASSO+Stepwise logistic regression,AUC为0.844。
- 增强CT模型采用Boruta+SVM,AUC为0.811。
- 平扫+增强CT联合模型采用LASSO+SVM,AUC为0.897。
- 外部验证中,平扫和增强模型单独预测ctDNA检测的T790M突变AUC分别为0.649和0.675,联合模型AUC为0.760。
临床应用与阅片要点
- 可结合CT形态学征象(外周位置、胸膜凹陷征)提示T790M突变风险。
- 推荐使用平扫联合增强CT的放射组学模型以提高预测效能。
局限性
- 外部验证中平扫和增强模型单独预测ctDNA检测的T790M突变效能有限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
RATIONALE AND OBJECTIVES: We aim to explore the value of chest CT radiomics in predicting the epidermal growth factor receptor (EGFR)-T790M resistance mutation of advanced non-small cell lung cancer (NSCLC) patients after the failure of first-line EGFR-tyrosine kinase inhibitor (EGFR-TKI).
MATERIALS AND METHODS: A total of 211 and 135 advanced NSCLC patients with tumor tissue-based (Cohort-1) or circulating tumor DNA (ctDNA)-based (Cohort-2) EGFR-T790M testing were included, respectively. Cohort-1 was used for modeling and Cohort-2 was for models' validation. Radiomic features were extracted from tumor lesions on chest nonenhanced CT (NECT) and/or contrast-enhanced CT (CECT). We used eight feature selectors and eight classifier algorithms to establish radiomic models. Models were evaluated by area under the receiver operating characteristic curve (AUC), calibration curve, and decision curve analysis (DCA).
RESULTS: CT morphological manifestations of peripheral location and pleural indentation sign were associated with EGFR-T790M. For NECT, CECT, and NECT+CECT radiomic features, the feature selector and classifier algorithms of LASSO and Stepwise logistic regression, Boruta and SVM, and LASSO and SVM were chosen to develop the optimal model, respectively (AUC: 0.844, 0.811, and 0.897). All models performed well in calibration curves and DCA. Independent validation of models in Cohort-2 revealed that both NECT and CECT models individually had limited power for predicting EGFR-T790M mutation detected by ctDNA (AUC: 0.649, 0.675), while the NECT+CECT radiomic model had a satisfactory AUC (0.760).
CONCLUSION: This study proved the feasibility of using CT radiomic features to predict the EGFR-T790M resistance mutation, which could be helpful in guiding personalized therapeutic strategies.
引用
- Tang, Li, Shen, et al. CT Radiomics Predict EGFR-T790M Resistance Mutation in Advanced Non-Small Cell Lung Cancer Patients After Progression on First-line EGFR-TKI. Acad Radiol. 2023. PMID: 36941156. doi:10.1016/j.acra.2023.01.040
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。